Securities code: Yifan Pharmaceutical Co.Ltd(002019) securities abbreviation: Yifan Pharmaceutical Co.Ltd(002019) Announcement No.: 2022026 Yifan Pharmaceutical Co.Ltd(002019)
Announcement on the application of the company and its holding company to financial institutions for credit lines and guarantee lines within the scope of the company’s consolidated statements
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
hot tip
1. The company and its subsidiaries are expected to provide a guarantee with a maximum amount of no more than RMB 450 million for the companies within the consolidation scope (including the wholly-owned and holding subsidiaries newly established or acquired within the expected guarantee approval period) in the next 12 months, including a total amount of RMB 200 million for the companies within the consolidation scope with an asset liability ratio of more than 70%, Provide a total guarantee amount of 4300000 yuan to companies within the consolidation scope with asset liability ratio less than 70%.
2. This time, the company within the scope of consolidation will be provided with a guarantee limit of no more than 450 million yuan, accounting for 52.72% of the audited net assets of the company in 2021.
1、 Overview of guarantee
Yifan Pharmaceutical Co.Ltd(002019) (hereinafter referred to as “the company”), the 23rd Meeting of the 7th board of directors deliberated and adopted the proposal on the company and its holding company applying for credit line from financial institutions and guarantee line within the scope of the company’s consolidated statements. In order to meet the needs of the company’s production and operation, ensure the normal capital turnover of the company and its holding company and ensure the sustainable development of production and operation, The company and the holding company intend to apply for comprehensive credit financing with a total amount of no more than RMB 500 million (or equivalent foreign currency) from various financial institutions, and the companies (including wholly-owned and holding subsidiaries newly established or acquired within the expected guarantee approval period) applying for inclusion in the company’s consolidated statements provide mutual guarantee, with a total guarantee amount of no more than RMB 450 million (or equivalent foreign currency), of which, Provide a total amount of guarantee of RMB 200 million for companies with an asset liability ratio of more than 70%, and a total amount of guarantee of RMB 430 million for companies with an asset liability ratio of less than 70%. The amount of guarantee can be adjusted among the above companies;
However, when the adjustment occurs, the guarantee object with an asset liability ratio of more than 70% can only be guaranteed from an asset liability ratio of more than 70%
70% of the guaranteed objects obtain the guarantee amount.
The authorization period of this external guarantee limit is 12 months from the date of deliberation and approval of the 2021 annual general meeting of shareholders
It is valid within the limit and can be recycled within the limit. The balance at any time point does not exceed RMB 450 million (or
Within the guarantee limit of equivalent foreign currency), the board of directors shall request the general meeting of shareholders to authorize the chairman of the company to be responsible for the specific organization and implementation
Implement and sign relevant contracts and documents, and the guarantee period shall be subject to the signed guarantee agreement.
According to relevant regulations, this external guarantee matter still needs to be submitted to the 2021 annual general meeting of shareholders for deliberation
This item does not constitute a connected transaction.
2、 Expected details of guarantee amount
The total amount of this guarantee does not exceed RMB 450 million, accounting for the company’s total amount as of December 31, 2021
The proportion of audited net assets and total assets was 52.72% and 36.99% respectively. Details of the above new guarantee amount
As follows:
Unit: 10000 yuan
Up to now, the company’s holding of the guaranteed party guarantees the proportion of this guarantee amount in the shares of the guaranteed party whether the company is related to the guarantor or not. The balance of assets in the latest period and the proportion of net joint guarantee liability ratio assets in the latest period of the company
Hefei Yifan biological 100% 55.66% 88 Ping An Bank Co.Ltd(000001) 1 Csg Holding Co.Ltd(000012) .89% no Pharmaceutical Co., Ltd
Hangzhou Xinfu technology 100% 60.71% 1129345914 Konka Group Co.Ltd(000016) .40% no Co., Ltd
Sichuan Defeng pharmaceutical 100% 12.50% 16 China Vanke Co.Ltd(000002) 00002.34% no
Suzhou Yifan Pharmaceutical Co., Ltd. 100% 15.91% 14814094911300 1.32% no
Hefei Yifan biological medicine Hefei Yifan biological – 69.19% 316 Shenzhen Sed Industry Co.Ltd(000032) 0003.75% no Pharmaceutical Co., Ltd. Pharmaceutical Co., Ltd
Hefei Yifan Biological Medicine Co., Ltd. – 25.27% 350 China Tianying Inc(000035) 0004.10%
Tianchang Yifan Pharmaceutical Co., Ltd. 100% – 13.62% – 5000 0.59%
Chongqing Xinfu Chemical Co., Ltd. 100% – 29.54% – 5000 0.59%
Anqing Xinfu Chemical Co., Ltd
Company Engineering Co., Ltd. 100% 12.47% – 5000 0.59% no company
Huzhou Xinfu New Material Co., Ltd. 100% 9.36% – 5000 0.59%
Up to now, the company’s holding of the guaranteed party guarantees the proportion of this guarantee amount in the shares of the guaranteed party whether the company is related to the guarantor or not. The balance of assets in the latest period and the proportion of net joint guarantee liability ratio assets in the latest period of the company
Yifan International Pharmaceutical Co., Ltd. scigen Pte Ltd 100% 22.88% 1632981700 0.20%
100% 1.68% – 5000 0.59% Yifan International Pharmaceutical Co., Ltd
NovoTek
Pharmaceuticals 100% 14.37% – 5000 0.59% no Limited
Xinfu Technology Co., Ltd. no 100% 47.18% – 500005.86%
Yiyi biomedicine
Company development (Shanghai) has 66.49% 100.81% – 200002.34% no limited companies
Total 2866489845000052.72%
3、 Basic information of the guaranteed
The secured party, basic information and main financial indicators (monomer) are detailed in the annex below.
4、 Main contents of the guarantee agreement
The above-mentioned estimated guarantee amount has not yet occurred, and the guarantee agreement has not been signed. The specific guarantee amount, method
The term and other relevant terms shall be subject to the relevant guarantee agreements and other documents actually signed by the company and its subsidiaries.
5、 Opinions of the board of directors
The company applies to financial institutions for credit lines and provides mutual guarantees between companies within the scope of consolidated statements
They are all the reasonable needs of the company’s normal operation, project construction, technology purchase and other investments, in line with the overall requirements of the company
Interests, agree to the company’s credit granting and guarantee, and agree to submit it to the 2021 annual general meeting of shareholders of the company for review
Discussion.
The guarantors are the company and all wholly-owned and holding subsidiaries respectively. Production and operation activities of the company and its wholly-owned subsidiaries
The company is in a normal state and has good solvency. The company’s guarantee risk is small and will not be damaged
The interests of the company and small and medium-sized investors. All statements are within the scope of holding subsidiaries
The company has effective control over its operation and management, finance, investment, financing and other aspects
Fully grasp and monitor the cash flow of the guaranteed company, and the financial risk is under the effective control of the company
Therefore, other shareholders may not provide the same proportion of guarantee and counter guarantee.
6、 Accumulated total amount of external guarantees and overdue guarantees
As of the disclosure date of this report, the company’s external guarantee balance was 2.866 billion yuan, accounting for the company’s audited balance in 2021
33.58% of the net assets attributable to the parent company in the consolidated statements are mutual guarantees between the company and its wholly-owned subsidiaries or wholly-owned subsidiaries. The company and its holding subsidiaries did not provide guarantees for units outside the scope of the consolidated statements, nor did they have the accumulated amount of overdue guarantees, the amount of guarantees involved in litigation and the amount of losses that should be borne due to the judgment of losing the guarantee.
7、 Documents for future reference
1. Resolution of the 23rd session of the 7th board of directors
2. Independent opinions of independent directors on matters related to the 23rd Meeting of the seventh board of directors
It is hereby announced.
Yifan Pharmaceutical Co.Ltd(002019) board of directors April 13, 2022
enclosure:
Unit: 10000 yuan
